Expression of chloride channel protein CLC-3 in patients with allergic rhinitis: effect of topical corticosteroid treatment

Arch Otolaryngol Head Neck Surg. 2008 Mar;134(3):301-5. doi: 10.1001/archoto.2007.45.

Abstract

Objectives: To determine whether the chloride channel protein CLC-3 is upregulated in patients with allergic rhinitis (AR) and whether topical corticosteroid treatment decreases the expression of CLC-3.

Design: Histologic study.

Setting: Academic research.

Patients: Eighteen patients with AR were included in the study.

Main outcome measures: Expression of CLC-3 was detected by immunohistochemistry and by reverse transcription-polymerase chain reaction before and at 4 weeks after treatment with the topical corticosteroid mometasone furoate.

Results: Strong CLC-3 expression was detected in epithelium and in submucosal glands. An increased presence of CLC-3 was demonstrated in nasal mucosa compared with that in normal nasal tissue. A statistically significant difference in CLC-3 gene expression level was found in nasal tissues before vs at 4 weeks after treatment with mometasone.

Conclusions: CLC-3 may have a role in modulating the pathogenesis of AR. Decreased expression of CLC-3 may be the mechanism of action of corticosteroid treatment in controlling AR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Anti-Allergic Agents / administration & dosage*
  • Chloride Channels / metabolism*
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Male
  • Middle Aged
  • Mometasone Furoate
  • Nasal Mucosa / metabolism*
  • Pregnadienediols / administration & dosage*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Rhinitis, Allergic, Perennial / drug therapy*
  • Rhinitis, Allergic, Perennial / metabolism*
  • Statistics, Nonparametric
  • Up-Regulation

Substances

  • Anti-Allergic Agents
  • Chloride Channels
  • ClC-3 channel
  • Pregnadienediols
  • Mometasone Furoate